Picture this: you’ve been an alcoholic for 30 years. It’s gotten so bad that you’re either constantly hungover or throwing up. You want to end your life. You want to get better. But nothing’s working.
For Maura Cohen’s patient, this was his reality – every day.
Then one day, someone suggested Special K infusions – and everything changed.
After several Special K therapy sessions, the patient began to go through a remarkable transformation – he started getting better.1
The same has been said of many patients trying out this revolutionary technique. Where other treatment methods have failed, psychedelics appears to help many mental health conditions.
It is the prospect of such results that has seen a number of psychedelics stocks targeting mental health disorders, like Compass Pathways and Mind Medicine, exponentially increase their valuations.
But for investors looking to get in on the ground stages of what has the potential to become the next big play in mental health, Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) could be a great place to start.
The company is leveraging the effectiveness of Special K to help alleviate the symptoms of a variety of mental health conditions and looks set to transform the whole space based on a number of factors.
Let’s dig in.
5 Reasons
Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) Could Revolutionize Mental Health
1
PAP clinics have an addressable market opportunity of $10 billion.
2
Pioneer and first mover advantage with Neurovo, which has over 100 clinics under management worldwide and hundreds of thousands of new patient inquiries.
3
Already generating cash flow with 2020 normalized revenue of $1.3 million and EBITDA of $380,000.
4
Team is made up of operators and marketers with over 30 years of combined experience in psychedelic administration.
5
Well funded after raising $2.4 million at $0.30 per share in January this year.
Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO)’s Multipronged Approach to the Mental Health Space
Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) makes use of cutting edge, evidence-based methods to address mental health symptoms and pain conditions. The company was founded in early 2018 by lead nurse anesthesiologist Katie Walker, who decided she could no longer ignore the profound transformational benefits of combined medical and holistic therapies.
The company owns and operates psychedelic clinics that empower individuals toward an improved quality of life and well-being through comprehensive and compassionate care, and has become the gold standard for clinics around the country. Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) commenced operations on its flagship clinic in February 2018, and is on track to have at least 20 of these clinics across the US by the end of 2021.
The company has psychedelic-based solutions for depression, opioid addiction, and suicidal ideation.
In addition to this, Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) has a strong partnership with Neurovo, which will be working with Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) through its public marketing arm. Neurovo is the industry’s first dedicated media agency with over 100 clinics under management worldwide and is rapidly growing. It is the world’s largest network of digital properties in psychedelics, combining north of 800 websites globally. It’s on pace to control more internet traffic globally than any other company in the psychedelics medicine space.
Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) has set out an aggressive expansion plan that will entail building and acquiring more clinics to grow its presence in the US and globally. Using Neurovo’s proprietary digital data sets for patient lead generation, Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) will optimize targeted geographic locations, starting with financially stable demographics that have a lower cost of living.
A Market Opportunity Like No Other
Although insurance companies are not covering the actual Special K infusions at this time, they do help with the office visits, necessary monitoring, and administration fees that come with the infusion sessions, which can actually equate to as much as 70% coverage in many cases.
Once psychedelics are on the FDA approval list for these specific conditions, insurance companies will be mandated to cover the services, allowing greater consistency and access to care, which will help stabilize finances for newly established clinics in a shorter projected timeframe.
On top of that, Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) recently received Veteran Affairs license approval for reimbursement, which should be a clear indication on the future prospects of PAP clinics.
According to Stifel GMP’s recent research report, psychedelic-assisted psychotherapy (PAP) clinics have an addressable market opportunity of $10 billion to $11 billion in the US alone. And the demand for PAP clinics has been steadily growing.
Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO) plans to increase this penetration rate by acquiring a pipeline of clinics, with the goal of having 120 clinics under management by end of 2023 and revenue estimated to be in the range of $100 to $150 million.
To learn more about Revitalist Lifestyle and Wellness (CSE:CALM) (OTC:RVLWF) (FRA:4DO), click here.